Liquid Biopsy Global Market – Forecast to 2024

  • ID: 4481697
  • Report
  • Region: Global
  • 495 Pages
  • IQ4I Research & Consultancy Pvt. Ltd
1 of 6
The Liquid Biopsy Global Market is Projected to Reach $8,730.4 Million by 2024

FEATURED COMPANIES

  • Abbott Diagnostics
  • Biodesix, Inc
  • DNA Forensics Laboratory
  • Genomic Health, Inc
  • MDx Health
  • Premaitha Health, PLC
  • MORE

Liquid biopsy is process of obtaining non-solid tissue usually the blood and other body fluids (urine, saliva etc.) obtained non-invasively as a diagnosis and monitoring tool for disease such as cancer through identification of biomarker in form of cell-fee DNA or circulating tumor cells (CTC) to advance personalized medicine, and improve the quality of life. The groundbreaking discovery of cfDNA in 1948 has opened up new possibilities in the field of oncology, transplantation and non-invasive prenatal screening.

According to this analysis, the liquid biopsy global market is projected to reach $8,730.4 million by 2024. The liquid biopsy global market is segmented based on the biomarkers, applications, sample type, end-users and geography.

Biomarkers market is divided into circulating tumor cells (CTC), cell-free DNA and Exosomes & Others, among which, the Cell-free DNA market commanded the largest share. The utilization of circulating tumor cell as an invaluable research tool is expected to propel this market at a strong CAGR.

The applications market is divided into oncology testing, prenatal (NIPT) testing and transplantation diagnostics where oncology testing dominates the application market which is followed by prenatal testing (NIPT), however, the rapid adoption of cfDNA based transplantation diagnostics testing is expected to drive this market at high double digit CAGR.

The oncology testing market is further divided based on type of cancer tested into breast cancer, colorectal cancer, lung cancer, prostate cancer, melanoma, ovarian cancer and others, where, breast cancer commanded largest share in 2017, lung cancer is projected to grow at highest CAGR from 2017 to 2024. The oncology testing market is further divided based on type of cancer care into early screening, companion diagnostics, prognosis and recurrence monitoring. The companion diagnostics monitoring market dominates the market in 2017, while early screening is expected to grow at strong CAGR.

The liquid biopsy sample market is divided into blood, urine and others where blood dominates the market in 2017 and is expected to maintain the position with strong CAGR growth from 2017 to 2024.

The end-users market is segmented into Hospitals and academic and research institutes. Hospitals attracted the largest revenue in 2017. The hospitals segment is expected to show strong CAGR growth from 2017 to 2027.

The liquid biopsy geographical market consists of North America, Europe, Asia-Pacific and RoW, where, North America dominates the market in 2017 followed by Europe with Asia-Pacific market expected to show highest growth from 2017 to 2024.

The report provides an in depth market analysis of the above mentioned segments across the following regions:

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (RoW)
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Abbott Diagnostics
  • Biodesix, Inc
  • DNA Forensics Laboratory
  • Genomic Health, Inc
  • MDx Health
  • Premaitha Health, PLC
  • MORE

1 Executive Summary

2 Introduction
2.1 Key Take Aways
2.2 Report Description
2.3 Markets Covered
2.4 Stakeholders
2.5 Research Methodology
2.5.1 Market Size Estimation
2.5.2 Market Crackdown And Datatriangulation
2.5.3 Secondary Sources
2.5.4 Key Data Points From Secondary Sources
2.5.5 Primary Sources
2.5.6 Key Data Points From Primary Sources
2.5.7 Assumptions

3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers And Opportunities
3.3.1.1 Rising Incidence Of Cancer
3.3.1.2 Increasing Preference For Blood/Urine Based Liquid Biopsy Over Invasive Tissue Biopsy Procedures
3.3.1.3 Rising Number Of Late Pregnancies Leading To High Incidence Rate Of Babies With Chromosomal Disorders
3.3.1.4 Increasing Funding For Liquid Based Test Development
3.3.1.5 Technological Advancements In Liquid Biopsy
3.3.1.6 Agreements And Collaborations
3.3.1.7 Increasing Number Of Liquid Biopsy Test Launches
3.3.2 Restraints And Threats
3.3.2.1 High Cost With Less Reimbursement Facilities
3.3.2.2 Ethical Issues Related To Genetic Testing
3.3.2.3 Lack Of Skilled Healthcare Professionals
3.3.2.4 Lack Of Standardization Of Liquid Biopsy Tests
3.3.2.5 Regulatory Issues
3.4 Regulatory Affairs
3.4.1 U.S.
3.4.2 Europe
3.4.3 China
3.4.4 India
3.4.5 Japan
3.5 Porter’S Five Force Analysis
3.5.1 Threat Of New Entrants
3.5.2 Threat Of Substitutes
3.5.3 Competitive Rivalry
3.5.4 Bargaining Power Of Suppliers
3.5.5 Bargaining Power Of Buyers
3.6 Patent Trends
3.7 Market Share Analysis
3.8 Reimbursement Scenario
3.9 Clinical Trials
3.10 Technological Advancements
3.10.1 Microrna (Mirna)
3.10.2 Protein Biomarkers
3.10.3 Circulating Mrna
3.10.4 Crispr Paper Test (Sherlock)
3.11 Upcoming Tests
3.12 Research Use Only Cell-Free Dna Tests
3.13 Funding Scenario
3.14 Liquid Biopsy Company Comparison By Applications

4 Market Sizing
4.1 U.S.Liquid Biopsy Market Sizing Information
4.1.1 Oncology Testing
4.1.1.1 Early Screening
4.1.1.2 Companion Diagnostics
4.1.1.3 Prognosis Monitoring
4.1.1.4 Recurrence Monitoring
4.1.2 Non-Invasive Prenatal Screening (Nipt)
4.1.3 Transplantation Diagnostics

5 Liquid Biopsy Global Market, By Biomarker
5.1 Introduction
5.2 Circulating Tumour Cells (Ctc)
5.3 Cell-Free Dna (Cfdna)
5.4 Exosomes & Others

6 Liquid Biopsy Global Market, By Application
6.1 Introduction
6.2 Oncology Testing
6.2.1 Cancer Types
6.2.1.1 Introduction
6.2.1.2 Lung Cancer
6.2.1.3 Breast Cancer
6.2.1.4 Colorectal Cancer
6.2.1.5 Melanoma
6.2.1.6 Prostate Cancer
6.2.1.7 Ovarian Cancer
6.2.1.8 Others
6.2.2 Cancer Care
6.2.2.1 Introduction
6.2.2.2 Early Screening
6.2.2.3 Companion Diagnosis
6.2.2.4 Prognosis Monitoring
6.2.2.5 Recurrence Monitoring
6.3 Prenatal Testing
6.4 Transplantation

7 Liquid Biopsy Global Market, By Sample
7.1 Introduction
7.2 Blood
7.3 Urine And Others

8 Liquid Biopsy Global Market, By End-Users
8.1 Introduction
8.2 Hospitals
8.3 Academic & Research Institutes

9 Regional Analysis
9.1 Introduction
9.2 North America
9.2.1 United States
9.2.2 Others
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 U.K.
9.3.4 Others
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Others
9.5 Rest Of The World (Row)
9.5.1 Brazil
9.5.2 Rest Of Latin America
9.5.3 Middle East & Others

10 Competitive Landscape
10.1 Introduction
10.2 Agreements
10.3 Collaborations/Partnerships
10.4 New Product Launches
10.5 Approvals
10.6 Acqustions
10.7 Others

11 Major Companies
11.1 Bgi (Bgi Diagnostics)
11.1.1 Overview
11.1.2 Financials
11.1.3 Products  Nifty Test
11.1.4 Key Developments
11.1.5 Business Strategy
11.1.6 Swot Analysis
11.2 Biocept, Inc.
11.2.1 Overview
11.2.2 Financials
11.2.3 Product Portfolio
11.2.4 Key Developments
11.2.5 Business Strategy
11.2.6 Swot Analysis
11.3 Caredx, Inc.
11.3.1 Overview
11.3.2 Financials
11.3.3 Product Description
11.3.4 Key Developments
11.3.5 Business Strategy
11.3.6 Swot Analysis
11.4 Cynvenio Biosystems, Inc
11.4.1 Overview
11.4.2 Financials
11.4.3 Product Portfolio
11.4.4 Key Developments
11.4.5 Business Strategy
11.4.6 Swot Analysis
11.5 Eurofins Scientific Se (Lifecodexx)
11.5.1 Overview
11.5.2 Financials
11.5.3 Product Portfolio
11.5.4 Key Developments
11.5.5 Business Strategy
11.5.6 Swot Analysis
11.6 Exact Sciences Corporation
11.6.1 Overview
11.6.2 Financials
11.6.3 Product Portfolio
11.6.4 Key Developments
11.6.5 Business Strategy
11.6.6 Swot Analysis
11.7 Exosome Diagnostics, Inc
11.7.1 Overview
11.7.2 Financials
11.7.3 Product Portfolio
11.7.4 Key Developments
11.7.5 Business Strategy
11.7.6 Swot Analysis
11.8 Guardant Health, Inc.
11.8.1 Overview
11.8.2 Financials
11.8.3 Product Description
11.8.4 Key Developments
11.8.5 Business Strategy
11.8.6 Swot Analysis
11.9 Illumina, Inc.
11.9.1 Overview
11.9.2 Financials
11.9.3 Product Portfolio
11.9.4 Key Developments
11.9.5 Business Strategy
11.9.6 Swot Analysis
11.10 Immucor
11.10.1 Overview
11.10.2 Financials
11.10.3 Product Portfolio
11.10.4 Key Developments
11.10.5 Business Strategy
11.10.6 Swot Analysis
11.11 Laboratory Corporation Of America Holdings
11.11.1 Overview
11.11.2 Financials
11.11.3 Product Portfolio
11.11.4 Key Developments
11.11.5 Business Strategy
11.11.6 Swot Analysis
11.12 Mdx Health
11.12.1 Overview
11.12.2 Financials
11.12.3 Product Description
11.12.4 Key Developments
11.12.5 Business Strategy
11.12.6 Swot Analysis
11.13 Myriad Genetics, Inc.
11.13.1 Overview
11.13.2 Financials
11.13.3 Product Portfolio
11.13.4 Key Developments
11.13.5 Business Strategy
11.13.6 Swot Analysis
11.14 Natera, Inc.
11.14.1 Overview
11.14.2 Financials
11.14.3 Product Portfolio
11.14.3.1 Panorama
11.14.3.2 Constellation
11.14.3.3 Signatera
11.14.3.4 Vistara
11.14.4 Key Developments
11.14.5 Business Strategy
11.14.6 Swot Analysis
11.15 Roche Holdings Ag
11.15.1 Overview
11.15.2 Financials
11.15.3 Product Description
11.15.4 Key Developments
11.15.5 Business Strategy
11.15.6 Swot Analysis

List Of Tables
Table 1 Liquid Biopsy Global Market Revenue, By Region (2016-2024) ($Mn)
Table 2 Liquid Biopsy Global Market Revenue, By Biomarkers (2016-2024) ($Mn)
Table 3 Liquid Biopsy Global Market Revenue, By Applications, (2016-2024) ($Mn)
Table 4 Liquid Biopsy Global Market Revenue, By Sample (2016-2024) ($Mn)
Table 5 Liquid Biopsy Global Market Revenue, By End-Users (2016-2024) ($Mn)
Table 6 Oncology Testing U.S. Market
Table 7 Nipt Global Total Addressable Market (Tam) (High Risk Pregnancies) (2017)($Mn)
Table 8 Kidney Transplantation Diagnostics Global Total Addressable Market (Tam) (2017)($Mn)
Table 9 Heart Transplantation Diagnostis Global Total Addressable Market (Tam) (2017)($Mn)
Table 10 Liquid Biopsy Global Market Revenue, By Biomarker (2016-2024) ($Mn)
Table 11 Circulating Tumor Cells Global Market Revenue, By Region (2016-2024) ($Mn)
Table 12 Cell-Free Dna Global Market Revenue, By Region (2016-2024) ($Mn)
Table 13 Exosomes & Others Global Market Revenue, By Region (2016-2024) ($Mn)
Table 14 Liquid Biopsy Global Market Revenue, By Applications (2016-2024) ($Mn)
Table 15 Oncology Testing Global Market Revenue, By Cancer Type (2016-2024) ($Mn)
Table 16 Oncology Testing Global Market Revenue, By Region (2016-2024) ($Mn)
Table 17 Lung Cancer Global Market Revenue, By Region (2016-2024) ($Mn)
Table 18 Breast Cancer Global Market Revenue, By Region (2016-2024) ($Mn)
Table 19 Colorectal Cancer Global Market Revenue, By Region (2016-2024) ($Mn)
Table 20 Melanoma Global Market Revenue, By Region (2016-2024) ($Mn)
Table 21 Prostate Cancer Global Market Revenue, By Region (2016-2024) ($Mn)
Table 22 Ovarian Cancer Global Market Revenue, By Region (2016-2024) ($Mn)
Table 23 Others Global Market Revenue, By Region (2016-2024) ($Mn)
Table 24 Oncology Testing Global Market Revenue, By Cancer Care (2016-2024) ($Mn)
Table 25 Early Screening Global Market Revenue, By Region (2016-2024) ($Mn)
Table 26 Companion Diagnostics Global Market Revenue, By Region (2016-2024) ($Mn)
Table 27 Prognosis Global Market Revenue, By Region (2016-2024) ($Mn)
Table 28 Recurrence Monitoring Global Market Revenue, By Region (2016-2024) ($Mn)
Table 29 Prenatal (Nipt) Testing Global Market Revenue, By Region (2016-2024) ($Mn)
Table 30 Transplantation Diagnostics Global Market Revenue, By Region (2016-2024) ($Mn)
Table 31 Liquid Biopsy Global Market Revenue, By Sample (2016-2024) ($Mn)
Table 32 Blood Sample Global Market Revenue, By Region (2016-2024) ($Mn)
Table 33 Urine & Other Samples Global Market Revenue, By Region (2016-2024) ($Mn)
Table 34 Liquid Biopsy Global Market Revenue, By End-Users,(2016-2024) ($Mn)
Table 35 Hospitals Global Market Revenue, By Region (2016-2024) ($Mn)
Table 36 Academic & Research Institutes Global Market Revenue, By Region (2016-2024) ($Mn)
Table 37 Liquid Biopsy Global Market Revenue, By Region (2016-2024) ($Mn)
Table 38 North America Liquid Biopsy Market Revenue, By Biomarkers (2016-2024) ($Mn)
Table 39 North America Liquid Biopsy Market Revenue, By Application (2016-2024) ($Mn)
Table 40 North America Oncology Testing Market Revenue, By Cancer Care (2016-2024) ($Mn)
Table 41 North America Oncology Testing Market Revenue, By Cancer Type (2016-2024) ($Mn)
Table 42 North Amerca Liquid Biopsy Market Revenue, By Sample (2016-2024) ($Mn)
Table 43 North America Liquid Biopsy Market Revenue, By End-Users, (2016-2024) ($Mn)
Table 44 North America Liquid Biopsy Market Revenue, By Country, (2016-2024) ($Mn)
Table 45 Europe Liquid Biopsy Market Revenue, By Biomarkers (2016-2024) ($Mn)
Table 46 Europe Liquid Biopsy Market Revenue, By Application (2016-2024) ($Mn)
Table 47 Europe Oncology Testing Market Revenue, By Cancer Care (2016-2024) ($Mn)
Table 48 Europe Oncology Testing Market Revenue, By Cancer Type (2016-2024) ($Mn)
Table 49 Europe Liquid Biopsy Market Revenue, By Sample (2016-2024) ($Mn)
Table 50 Europe Liquid Biopsy Market Revenue, By End-Users, (2016-2024) ($Mn)
Table 51 Europe Liquid Biopsy Market Revenue, By Country, (2016-2024) ($Mn)
Table 52 Asia-Pacific Liquid Biopsy Market Revenue, By Biomarkers (2016-2024) ($Mn)
Table 53 Asia-Pacific Liquid Biopsy Market Revenue, By Application (2016-2024) ($Mn)
Table 54 Asia-Pacific Oncology Testing Market Revenue, By Cancer Care (2016-2024) ($Mn)
Table 55 Asia-Pacific Oncology Testing Market Revenue, By Cancer Type (2016-2024) ($Mn)
Table 56 Asia-Pacific Liquid Biopsy Market Revenue, By Sample (2016-2024) ($Mn)
Table 57 Asia-Pacific Liquid Biopsy Market Revenue, By End-Users, (2016-2024) ($Mn)
Table 58 Asia-Pacific Liquid Biopsy Market Revenue, By Country, (2016-2024) ($Mn)
Table 59 Row Liquid Biopsy Market Revenue, By Biomarkers (2016-2024) ($Mn)
Table 60 Row Liquid Biopsy Market Revenue, By Application (2016-2024) ($Mn)
Table 61 Row Oncology Testing Market Revenue, By Cancer Care 2016-2024) ($Mn)
Table 62 Row Oncology Testing Market Revenue, By Cancer Type (2016-2024) ($Mn)
Table 63 Row Liquid Biopsy Market Revenue, By Sample (2016-2024) ($Mn)
Table 64 Row Liquid Biopsy Market Revenue, By End-Users (2016-2024) ($Mn)
Table 65 Row Liquid Biopsy Market Revenue, By Country, (2016-2024) ($Mn)
Table 66 Agreements (2016-2018)
Table 67 Collaborations/Partnerships (2016-2018)
Table 68 New Product Launch (2016-2018)
Table 69 Approvals (2016-2018)
Table 70 Acquisitions (2016-2018)
Table 71 Others (2016-2018)
Table 72 Biocept, Inc: Total Revenue And R&D Expenses 2015-2017 ($Mn)
Table 73 Caredx, Inc.: Total Revenue And R&D Expenses (2015-2017) ($Mn)
Table 74 Caredx, Inc.: Total Revenue, By Segments (2015-2017) ($Mn)
Table 75 Caredx, Inc.: Total Revenue, By Geography (2015-2017) ($Mn)
Table 76 Eurofins Scientific: Total Revenue And R&D Expenses (2015-2017) ($Mn)
Table 77 Eurofins Scientific: Total Revenue, By Geography (2015-2017) ($Mn)
Table 78 Exact Sciences Corporation: Total Revenue And R&D Expenses, (2015-2017) ($Mn)
Table 79 Illumina Inc: Total Revenue And R&D Expenses (2015-2017) ($Mn)
Table 80 Illumina Inc: Total Revenue, By Segment, (2015-2017) ($Mn)
Table 81 Illumina Inc: Total Revenue, By Geography (2015-2017) ($Mn)
Table 82 Immucor Inc.: Total Revenue And R&D Expenses, (2014-2016) ($Mn)
Table 83 Immucor Inc.: Total Revenue, By Segments, (2014-2016) ($Mn)
Table 84 Immucor Inc.: Total Revenue, By Geography (2014-2016) ($Mn)
Table 85 Labcorp.: Total Revenue And R&D Expenses, (2015-2017) ($Mn)
Table 86 Labcorp.: Total Revenue, By Segment, (2015-2017) ($Mn)
Table 87 Labcorp.: Total Revenue, By Geography, (2015-2017) ($Mn)
Table 88 Mdxhealth: Total Revenue And R&D Expenses, (2015-2017) ($Mn)
Table 89 Myraid Genetics: Total Revenue And R&D Expenses, (2015-2017) ($Mn)
Table 90 Myriad Genetics, Inc.: Total Revenue, By Segments, (2015-2017) ($Mn)
Table 91 Natera, Inc.: Total Revenue And R&D Expenses, (2015-2017) ($Mn)
Table 92 Natera, Inc.: Total Revenue, By Geography, (2015-2017) ($Mn)
Table 93 Roche Holdings Ag: Total Revenue And R&D Expenses, (2015-2017) ($Mn)
Table 94 Roche Holdings Ag: Total Revenue By Segments (2015-2017) ($Mn)
Table 95 Roche Holdings Ag: Diagnostics Revenue By Types (2015-2017) ($Mn)
Table 96 Roche Holdings Ag: Total Revenue, By Geography, (2015-2017) ($Mn)

List Of Figures
Figure 1 Liquid Biopsy Global Market Revenue & Share, By Geography, (2016-2024) ($Mn)
Figure 2 Liquid Biopsy Global Market: Research Approach
Figure 3 Liquid Biopsy Global Market: Top-Down And Bottom-Up Approach
Figure 4 Liquid Biopsy Global Market: Forecasting Model
Figure 5 Liquid Biopsy Global Market: Market Crackdown And Data Triangulation
Figure 6 Liquid Biopsy Global Market: Market Segmentation
Figure 7 Market Dynamics
Figure 8 Liquid Biopsy Global Market: Porter’S Analysis
Figure 9 Liquid Biopsy Global Market: Pct Filing By Major Players (2013-2017)
Figure 10 Liquid Biopsy Market Share Analysis By Major Players (2017) (%)
Figure 11 Nipt Market Share Analysis By Major Players (2017) (%)
Figure 12 U.S. Liquid Biopsy Market: Total Addressable Market (Tam) ($Mn)
Figure 13 Liquid Biopsy Global Market Revenue, By Biomarker, (2017 Vs 2024) ($Mn)
Figure 14 Circulating Tumor Cells Global Market Revenue, By Region (2016-2024) ($Mn)
Figure 15 Cell-Free Dna Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 16 Exosome & Others Dna Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 17 Liquid Biopsy Global Market Revenue, By Application, (2017 Vs 2024) ($Mn)
Figure 18 Oncology Testing Global Market Share, By Cancer Type (2017) (%)
Figure 19 Oncology Testing Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 20 Lung Cancer Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 21 Breast Cancer Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 22 Colorectal Cancer Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 23 Melanoma Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 24 Prostate Cancer Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 25 Ovarian Cancer Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 26 Others Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 27 Early Screening Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 28 Companion Diagnostics Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 29 Prognosis Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 30 Recurrence Monitoring Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 31 Prenatal (Nipt) Testing Global Market Revenue,By Region (2017 Vs 2024) ($Mn)
Figure 32 Transplantation Diagnostics Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 33 Liquid Biopsy Global Market Revenue, By Sample, (2017 Vs 2024) ($Mn)
Figure 34 Blood Sample Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 35 Urine & Other Samples Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 36 Liquid Biopsy Global Market Revenue, By End-Users, (2017 Vs 2024) ($Mn)
Figure 37 Hospitals Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 38 Academic & Research Institutes Global Market Revenue, By Region (2017 Vs 2024) ($Mn)
Figure 39 Liquid Biopsy Global Market Revenue, By Geography, (2016-2024) ($Mn)
Figure 40 North America Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 41 North America Liquid Biopsy Market Revenue, By Application And Cancer Care (2017) ($Mn)
Figure 42 North America Oncology Testing Market Share, By Cancer Type (2017) (%) Cagr (%)
Figure 43 North America Liquid Biopsy Market Share, By Sample (2017 Vs 2024) (%)
Figure 44 North America Liquid Biopsy Market Share, By End-Users (2017 Vs 2024) (%)
Figure 45 North America Liquid Biopsy Market Revenue, By Country (2017 Vs 2024) ($Mn)
Figure 46 United States Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 47 U.S. Liquid Biopsy Market Revenue, By Application & Type (2017) ($Mn)
Figure 48 U.S. Liquid Biopsy Market Revenue, By Sample & By End-Users (2017 Vs 2024) ($Mn)
Figure 49 Other North American Countries Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 50 Other North American Countries Liquid Biopsy Market Revenue, By Application & Cancer Type (2017) ($Mn)
Figure 51 Other North American Countries Liquid Biopsy Market Revenue, By Sample & By End-Users (2017 Vs 2024) ($Mn)
Figure 52 Europe Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 53 Europe Oncology Testing Market Revenue, By Application And Cancer Care (2017) ($Mn)
Figure 54 Europe Oncology Testing Market Share, By Cancer Type (2017) (%)
Figure 55 Europe Liquid Biopsy Market Share, By Sample (2017 Vs 2024) (%)
Figure 56 Europe Liquid Biopsy Market Share, By End-Users (2017 Vs 2024) (%)
Figure 57 Europe Liquid Biopsy Market Revenue, By Country (2017 Vs 2024) ($Mn)
Figure 58 Germany Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 59 Germany Liquid Biopsy Market Revenue, By Application & Cancer Type (2017) ($Mn)
Figure 60 Germany Liquid Biopsy Market Revenue, By Sample & By End-Users (2017 Vs 2024) ($Mn)
Figure 61 France Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 62 France Liquid Biopsy Market Revenue, By Application & Cancer Type (2017) ($Mn)
Figure 63 France Liquid Biopsy Market Revenue, By Sample & By End-Users (2017 Vs 2024) ($Mn)
Figure 64 U.K. Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 65 U.K. Liquid Biopsy Market Revenue, By Application & Cancer Type (2017) ($Mn)
Figure 66 U.K. Liquid Biopsy Market Revenue, By Sample & By End-Users (2017 Vs 2024) ($Mn)
Figure 67 Other European Countries Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 68 Other European Countries Liquid Biopsy Market Revenue, By Application & Cancer Type (2017) ($Mn)
Figure 69 Other European Countries Liquid Biopsy Market Revenue, By Sample & By End-Users (2017 Vs 2024) ($Mn)
Figure 70 Asia-Pacific Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 71 Asia-Pacific Liquid Biopsy Market Revenue, By Application And Cancer Care (2017) ($Mn)
Figure 72 Asia-Pacific Oncology Testing Market Share, By Cancer Type (2017) (%)
Figure 73 Asia-Pacific Liquid Biopsy Market Share, By Sample (2017 Vs 2024) (%)
Figure 74 Asia-Pacific Liquid Biopsy Market Share, By End-Users (2017 Vs 2024) (%)
Figure 75 Asia-Pacific Liquid Biopsy Market Revenue, By Country (2017 Vs 2024) ($Mn)
Figure 76 Japan Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 77 Japan Liquid Biopsy Market Revenue, By Application & Type (2017) ($Mn)
Figure 78 Japan Liquid Biopsy Market Revenue, By Sample & By End-Users (2017 Vs 2024) ($Mn)
Figure 79 China Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 80 China Liquid Biopsy Market Revenue, By Application & Cancer Type (2017) ($Mn)
Figure 81 China Liquid Biopsy Market Revenue, By Sample & By End-Users (2017 Vs 2024) ($Mn)
Figure 82 India Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 83 India Liquid Biopsy Market Revenue, By Application & Cancer Type (2017) ($Mn)
Figure 84 India Liquid Biopsy Market Revenue, By Sample & By End-Users (2017 Vs 2024) ($Mn)
Figure 85 Other Apac Countries Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 86 Other Apac Countries Liquid Biopsy Market Revenue, By Application & Cancer Type (2017) ($Mn)
Figure 87 Other Apac Countries Liquid Biopsy Market Revenue, By Sample & By End-Users (2017 Vs 2024) ($Mn)
Figure 88 Row Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 89 Row Liquid Biopsy Market Revenue, By Application And Cancer Care (2017) ($Mn)
Figure 90 Row Oncology Testing Market Share, By Cancer Type (2017) (%)
Figure 91 Row Liquid Biopsy Market Share, By Sample (2017 Vs 2024) (%)
Figure 92 Row Liquid Biopsy Market Share, By End-Users (2017 Vs 2024) (%)
Figure 93 Row Liquid Biopsy Market Revenue, By Country (2017 Vs 2024) ($Mn)
Figure 94 Brazil Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 95 Brazil Liquid Biopsy Market Revenue, By Application & Cancer Type (2017) ($Mn)
Figure 96 Brazil Liquid Biopsy Market Revenue, By Sample & By End-Users (2017 Vs 2024) ($Mn)
Figure 97 Rest Of Latin America Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 98 Rest Of Latin America Liquid Biopsy Market Revenue, By Application & Cancer Type (2017) ($Mn)
Figure 99 Rest Of Latin America Liquid Biopsy Market Revenue, By Sample & By End-Users (2017 Vs 2024) ($Mn)
Figure 100 Middle East & Others Liquid Biopsy Market Revenue, By Biomarkers (2017 Vs 2024) ($Mn)
Figure 101 Middle East & Others Liquid Biopsy Market Revenue, By Application & Cancer Type (2017) ($Mn)
Figure 102 Middle East & Others Liquid Biopsy Market Revenue, By Sample & By End-Users (2017 Vs 2024) ($Mn)
Figure 103 Key Growth Strategies, (2016 – 2018)
Figure 104 Swot: Bgi
Figure 105 Swot: Biocept, Inc.
Figure 106 Swot: Caredx, Inc.
Figure 107 Swot: Cynvenio Biosystems, Inc.
Figure 108 Swot: Eurofins Scientific Se
Figure 109 Swot: Exact Sciences Corporation
Figure 110 Swot: Exosome Diagnostics
Figure 111 Swot: Guardant Health, Inc.
Figure 112 Swot: Illumina, Inc.
Figure 113 Swot: Immucor, Inc.
Figure 114 Swot: Laboratory Corporation Of America Holdings
Figure 115 Swot: Mdxhealth
Figure 116 Swot: Myriad Genetics
Figure 117 Swot: Natera, Inc.
Figure 118 Swot: Roche Holdings Ag

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Abbott Diagnostics
  • Biodesix, Inc
  • DNA Forensics Laboratory
  • Genomic Health, Inc
  • MDx Health
  • Premaitha Health, PLC
  • MORE

Liquid  biopsy  is  a  minimally  invasive  technology  for  the  detection  of  molecular  biomarkers without  the  need  for  invasive  procedures.  Circulating  tumor  cells  (CTCs),  Circulating  free DNA (cfDNA), exosomes and others (microvesicles & apoptotic bodies) in the blood can help in diagnosing the disease condition and give clues about which treatments are most likely to work  for  that  patient.  The  recent  interest  in  nucleic  acids  present  in  blood  and  urine  has opened  up  numerous  new  areas  of  investigation  and  new  possibilities  for  molecular diagnosis.

In  oncology,  tumor-derived  genetic  changes,  epigenetic  alterations,  and  viral nucleic  acids  have  been  found  in  the  plasma  or  serum  of  cancer  patients.  These  findings have important implications for the detection, monitoring, and prognostication of many types of  malignancies.  In  prenatal  diagnosis,  the  discovery  of  fetal  DNA  in  maternal  plasma  and serum  has  provided  a  non-invasive  source  of  fetal  genetic  material  for  analysis.  This development has important implications for the realization of non-invasive prenatal diagnosis and  has  provided  new  methods  for  the  monitoring  of  pregnancy-associated  disorders.

Plasma  DNA  technology  has  also  found  recent  applications  in  the  fields  of  organ transplantation,  infectious  agent  detection  and  monitoring.  Future  areas  of  study  include circulating  RNA  in  plasma  and  the  elucidation  of  the  biology  of  release,  clearance,  and possible functionality of plasma nucleic acids. 

According to this analysis, the liquid biopsy global market was estimated to reach $8,730.4 million  by  2024.  The  factors  driving  the  market  are  raising  incidence  of  cancer,  increasing preference  for  blood  or  urine  based  liquid  biopsy,  rising  number  of  late  pregnancies, technological  advancements,  increasing funding,  agreements  and collaborations. Whereas, factor  such  as  high  cost  of  tests  with  limited  reimbursements  and  regulatory  issues  are restraining the market growth. 

The  liquid  biopsy  market  is  divided  based  on  biomarkers,  applications,  sample,  end-users and  geography.  The  biomarkers  market  is  further  segmented  into  circulating  tumor  cells (CTCs),  Cell-free  DNA  and  exosomes  and  other,  among  them  Cell-free  DNA  commanded the largest share and circulating tumor cells are project to grow at highest CAGR from 2017 to 2024. The applications market is segmented into oncology testing, prenatal non-invasive testing  and  transplantation  diagnostics. 

The  oncology  testing  commanded  the  largest revenue  of  in  2017  and  transplantation  diagnostics  is  expected  to  show  highest  CAGR growth. The oncology testing market is further segmented based on type of cancer into lung, breast, colorectal, ovarian, prostate, melanoma and others. The breast cancer commanded the  largest  share  in  2017  and  lung  cancer  is  expected  to  grow  at  double  digit  CAGR  from 2017  to  2024.  In  segmentation  based  on  cancer  care,  the  application  market  consists  of early  screening,  companion  diagnostics,  prognosis  and  recurrence  monitoring.  The companion  diagnostics  commanded  the  largest  revenue  in  2017  where  as  recurrence monitoring is projected to grow at strong double digit CAGR from 2017 to 2024. 

The liquid biopsy market by sample source is segmented into blood and urine & others. The blood based tests commanded largest share of the market in 2017 and is project to maintain its  leading  position  from  2017  to  2024.  The  end-user  market  consist  of  Hospitals  and academic  &  research  institutes,  here  hospitals  leads  the  market  with  revenue  in  2017  and also projected to maintain the position till 2024.

Geographically, the market is segmented into North America, Europe, Asia-Pacific and RoW. The North America dominates the market with share in 2017 due to rising aging population, late pregnancies, preference for non-invasive tests where as Asia-Pacific is projected to be fastest  growing  market  with  high  CAGR  from  2017  to  2024  due  to  increasing  affluence, awareness and increasing incidence of cancer in the region. 

Technological  advancements  in  liquid  biopsy  are  expansion  of  applications  beyond  cancer diagnostics and monitoring to include other conditions such as cardiac health and infectious diseases and exploring of new sources for liquid biopsy such as miRNA, protein biomarkers and circulating MRNA. A paper based dip test called has been developed by scientists from Broad  institute  of  MIT  and  Harvard,  SHERLOCK,  that  make  use  of  Cas13  CRISPR associated protein that bind to specific RNA to identify specific targets. This test is expected to detect tumor DNA in the near future.

The  possibility  of  detection  of  health  condition  of  an  individual  based  on  simple  blood  test has  ignited  imagination of  scientific  community  and  a flurry  of  activity  has  been  unleashed. The  absence  of  rigorous  regulatory  requirement  as  in  case  of  a  drug  or  a  medical  device also reduces the time to market for these tests which is attracting private investments. Some of  the  recent  investments  are  funding  of  $40  million  to  MedGenome  Labs  Ltd  by  group  of investors  (HDFC,  Sequoia,  Sofina  s.a.  Zodiac  Capital  for  expansion  of  clinical  genomic testing of NIPT, Series C funding of DiaCarta in February 2018, to Support Company’s core XNA  technology  and  expansion  of  diagnostic  products.  Biggest  of  them  all  investment  of $900  million  in  GRAIL,  Inc  a  spinoff  of  Illumina  by  Johnson  &  Johnson  and  Jeff  Bezos  of Amazon for development of ctDNA based tests. 

Note: Product cover images may vary from those shown
5 of 6
  • Abbott Diagnostics
  • Adaptive biotechnologies
  • Admera health
  • Affinity DNA
  • Agena Bioscience, Inc
  • Agilent (Multiplicom)
  • AIOCARE Pvt Ltd (NIPTlab)
  • Ambry Genetics
  • Annoroad Gene Technology
  • Apollo Center for Fetal Medicine
  • ARUP Laboratories
  • Beijing Berry and Kang Biotechnology Co., Ltd (Berry Genom
  • BGI Diagnostics
  • Bioarray SL
  • Biocartis N.V.
  • Biocept, Inc
  • Biodesix, Inc
  • BioMarcare technologies
  • Bio-Rad Laboratories,
  • Boreal Genomics
  • Cancer Genetics, Inc
  • CareDx, Inc
  • CellMax Life
  • Chronix Biomedical
  • Circulogene theranostics
  • Cooper Genomics (Recombine)
  • Counsyl, Inc
  • Cynvenio Biosystems, Inc
  • Datar Genetics Limited
  • Diacarta, Inc
  • DiaDx
  • DNA Forensics Laboratory
  • DNA Labs India
  • Eone-Diagnomics Genome Center (EDGC)
  • Epic Sciences, Inc
  • Epicgenomics AG
  • Eurofins Scientific SE
  • Exact Sciences Corporation
  • Exosome Diagnostics, Inc
  • Foundation Medicine, Inc
  • Future health Biobank
  • GATC Biotech AG
  • GenePath Dx
  • GeneTech
  • Genetracer Biotech
  • Genome Care
  • Genomic Diagnostics
  • Genomic Health, Inc
  • Genoptix
  • Gensignia Life Sciences, Inc.
  • Guardant Health, Inc
  • Igenomix
  • Illumina, Inc
  • Immucor
  • ImpactLab Srl
  • Inivata limited
  • Integrated Diagnostics, Inc. (InDi Dx)
  • Invitae Corporation
  • LabCorp
  • Lab Genomics
  • Laboratory of Advanced Medicine (IvyGeneLabs)
  • LCM Genect Srl
  • LifeCell International Pvt. Ltd
  • Liquid biotech USA, Inc
  • MapMyGenome
  • MDx Health
  • Medgenome Labs Pvt. Ltd
  • Menarini Silicon Biosystems Inc
  • Metamark Genetics, Inc.
  • Microgenomics Srl
  • MiRXes pte Ltd
  • Molecular MD
  • Myriad Genetics,Inc
  • Natera, Inc
  • NeoGenomics Laboratories, Inc
  • NIPD Genetics Public Company Ltd
  • NxGen MDx LLC
  • Oncocyte corporation
  • OncoDNA S.A.
  • OPKO Health, Inc (Bio-reference Laboratories) (Genpath Diagnos
  • Pangaea oncology
  • Pathway genomics
  • Personal Genome Diagnostics, Inc
  • PGL Labs, LLC (Pernonalized Genomics)
  • Positive Bioscience
  • Premaitha Health, PLC
  • Progenity, Inc
  • Provista Diagnostics, Inc
  • ProXeom
  • Qiagen N.V.
  • Quest Diagnostics Incorporated
  • Resolution Biosciences, Inc
  • Roche Diagnostics
  • SAGA Diagnostics
  • Shanghai Genomatrix Medical Laboratory Co. Ltd.
  • Siemens (Neo New Oncology GmbH)
  • Sistemas Genomicos SL
  • Strand Life Sciences Pvt Ltd
  • SynapseDiagnostics
  • Synlab International
  • Sysmex Inostics GmbH
  • TAI Diagnostics
  • Trovagene, Inc
  • Vanadis diagnostics (Perkin Elmer)
  • Variantyx
  • Vermillion, Inc (Aspira Labs)
  • Victorian Clinical Genetics Services (VCGS)
  • VolitionRX Limited
  • Zer Laboratories, Ltd
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll